JP2006501249A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006501249A5 JP2006501249A5 JP2004532301A JP2004532301A JP2006501249A5 JP 2006501249 A5 JP2006501249 A5 JP 2006501249A5 JP 2004532301 A JP2004532301 A JP 2004532301A JP 2004532301 A JP2004532301 A JP 2004532301A JP 2006501249 A5 JP2006501249 A5 JP 2006501249A5
- Authority
- JP
- Japan
- Prior art keywords
- immunogen
- vaccine
- human
- sequence
- vaccine according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002163 immunogen Effects 0.000 claims 19
- 229960005486 vaccine Drugs 0.000 claims 18
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 claims 9
- 102000003816 Interleukin-13 Human genes 0.000 claims 9
- 108090000176 Interleukin-13 Proteins 0.000 claims 9
- 102000019207 human interleukin-13 Human genes 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 4
- 231100000252 nontoxic Toxicity 0.000 claims 3
- 230000003000 nontoxic effect Effects 0.000 claims 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 3
- 229930182490 saponin Natural products 0.000 claims 3
- 150000007949 saponins Chemical class 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0220211A GB0220211D0 (en) | 2002-08-30 | 2002-08-30 | Vaccine |
| GB0304672A GB0304672D0 (en) | 2003-02-28 | 2003-02-28 | Vaccines |
| PCT/GB2003/003729 WO2004019975A2 (en) | 2002-08-30 | 2003-08-28 | Il-14 vaccine for the treatment of asthma and atopic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006501249A JP2006501249A (ja) | 2006-01-12 |
| JP2006501249A5 true JP2006501249A5 (enExample) | 2006-06-15 |
Family
ID=31980002
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004532296A Pending JP2006503018A (ja) | 2002-08-30 | 2003-08-28 | ワクチン |
| JP2004532301A Pending JP2006501249A (ja) | 2002-08-30 | 2003-08-28 | ワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004532296A Pending JP2006503018A (ja) | 2002-08-30 | 2003-08-28 | ワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060104943A1 (enExample) |
| EP (2) | EP1534323A2 (enExample) |
| JP (2) | JP2006503018A (enExample) |
| AU (2) | AU2003259374A1 (enExample) |
| CA (2) | CA2496607A1 (enExample) |
| WO (2) | WO2004019975A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101073590B1 (ko) * | 2003-07-15 | 2011-10-14 | 메디뮨 리미티드 | Ｉｌ-13에 대한 인간 항체 분자 |
| PL1711528T3 (pl) | 2003-12-23 | 2012-11-30 | Genentech Inc | Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13 |
| US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| GB0600488D0 (en) * | 2006-01-11 | 2006-02-22 | Glaxo Group Ltd | Immunoglobulins |
| SE532249C2 (sv) * | 2006-11-13 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av IL-18 för behandling av olika inflammatoriska sjukdomar genom vaccinering |
| US9498525B2 (en) * | 2007-03-15 | 2016-11-22 | Hunter Immunology Limited | Treatment or prophylaxis of asthma |
| WO2008109957A1 (en) * | 2007-03-15 | 2008-09-18 | Hunter Immunology Limited | Method for determining suitability of treatment for asthma or chronic airways disease |
| BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
| CN105722532A (zh) | 2013-09-13 | 2016-06-29 | 豪夫迈·罗氏有限公司 | 包含纯化的重组多肽的方法和组合物 |
| EP3574915A1 (en) * | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| AU2022212600A1 (en) * | 2021-01-29 | 2023-08-17 | Bayer Animal Health Gmbh | Vaccine composition for breaking self-tolerance |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6296843B1 (en) * | 1998-04-03 | 2001-10-02 | The Penn State Research Foundation | Mutagenized IL 13-based chimeric molecules |
| WO2000065058A1 (en) * | 1999-04-23 | 2000-11-02 | Pharmexa A/S | Method for down-regulating il5 activity |
| EE200200025A (et) * | 1999-07-20 | 2003-04-15 | Pharmexa A/S | Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto |
| AU1599301A (en) * | 1999-11-11 | 2001-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Modulating IL-13 activity using mutated IL-13 molecules that are antagonists or agonists of IL-13 |
| US6846486B1 (en) * | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| JP2004511527A (ja) * | 2000-10-18 | 2004-04-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
| CA2496409A1 (en) * | 2002-08-30 | 2004-03-11 | Glaxo Group Limited | Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |
-
2003
- 2003-08-28 JP JP2004532296A patent/JP2006503018A/ja active Pending
- 2003-08-28 EP EP03791038A patent/EP1534323A2/en not_active Withdrawn
- 2003-08-28 WO PCT/GB2003/003729 patent/WO2004019975A2/en not_active Ceased
- 2003-08-28 AU AU2003259374A patent/AU2003259374A1/en not_active Abandoned
- 2003-08-28 CA CA002496607A patent/CA2496607A1/en not_active Abandoned
- 2003-08-28 EP EP03791033A patent/EP1534329A2/en not_active Withdrawn
- 2003-08-28 JP JP2004532301A patent/JP2006501249A/ja active Pending
- 2003-08-28 US US10/526,151 patent/US20060104943A1/en not_active Abandoned
- 2003-08-28 CA CA002496948A patent/CA2496948A1/en not_active Abandoned
- 2003-08-28 AU AU2003260748A patent/AU2003260748A1/en not_active Abandoned
- 2003-08-28 WO PCT/GB2003/003721 patent/WO2004019979A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006501249A5 (enExample) | ||
| Edelman | Survey of human-use adjuvants | |
| ES2257068T3 (es) | Mezclas de adyuvantes de cpg y saponinas y metodos de empleo de las mismas. | |
| Nobiron et al. | Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice | |
| HRP20090678T1 (hr) | Cjepivo za sprječavanje i liječenje infekcije hiv-om | |
| JP2009519309A5 (enExample) | ||
| KR100875483B1 (ko) | 백신 조성물 | |
| HRP20140484T1 (hr) | Cjepivni pripravci koji sadrže saponinski adjuvans | |
| AR035586A1 (es) | Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn | |
| RU2015139827A (ru) | МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP | |
| ME00183B (me) | Novi postupak za deregulaciju amiloida | |
| JP2006504653A5 (enExample) | ||
| WO2008140478A4 (en) | Compositions and methods for immunodominant antigens | |
| CA2704283A1 (en) | Vaccine | |
| Kenney et al. | Adjuvants for the future | |
| RU2008102930A (ru) | Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки | |
| AR053711A1 (es) | Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion | |
| JP2005502314A5 (enExample) | ||
| SI2538972T1 (en) | Recombinant CDV compositions and their uses | |
| JP2012524099A5 (enExample) | ||
| CA2409406A1 (en) | Qs-21 and il-12 as an adjuvant combination | |
| Gjorgievska et al. | Marginal adaptation and performance of bioactive dental restorative materials in deciduous and young permanent teeth | |
| CA2376926A1 (en) | Use of cpg as an adjuvant for malaria vaccine | |
| Christian et al. | All-ceramic partial coverage premolar restorations. Cavity preparation design, reliability and fracture resistance after fatigue | |
| Baer et al. | Periodontal disease in six strains of inbred mice |